State of Alaska Department of Revenue cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 8.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,933 shares of the specialty pharmaceutical company’s stock after selling 742 shares during the quarter. State of Alaska Department of Revenue’s holdings in Jazz Pharmaceuticals were worth $983,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Spire Wealth Management raised its position in Jazz Pharmaceuticals by 957.9% in the first quarter. Spire Wealth Management now owns 201 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 182 shares in the last quarter. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.4% in the 1st quarter. UMB Bank n.a. now owns 271 shares of the specialty pharmaceutical company’s stock worth $40,000 after purchasing an additional 112 shares in the last quarter. Archer Investment Corp increased its stake in Jazz Pharmaceuticals by 8,333.3% in the 1st quarter. Archer Investment Corp now owns 506 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 500 shares in the last quarter. Platinum Investment Management Ltd. purchased a new position in Jazz Pharmaceuticals in the 1st quarter worth about $90,000. Finally, Brown Brothers Harriman & Co. purchased a new position in Jazz Pharmaceuticals in the 1st quarter worth about $101,000. 88.15% of the stock is currently owned by institutional investors.
Jazz Pharmaceuticals Trading Up 5.3 %
Shares of NASDAQ JAZZ opened at $136.00 on Tuesday. The stock has a market cap of $8.58 billion, a price-to-earnings ratio of -86.62, a PEG ratio of 0.92 and a beta of 0.73. The business has a 50 day simple moving average of $135.10 and a 200 day simple moving average of $133.62. Jazz Pharmaceuticals plc has a 52 week low of $120.64 and a 52 week high of $160.96. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.49 and a current ratio of 3.18.
Analysts Set New Price Targets
JAZZ has been the topic of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $226.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 22nd. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $203.00 to $201.00 and set an “outperform” rating on the stock in a research note on Thursday, August 10th. Raymond James assumed coverage on Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a “market perform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $204.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, August 11th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $206.67.
View Our Latest Analysis on JAZZ
Insider Buying and Selling
In related news, EVP Neena M. Patil sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $144.25, for a total value of $216,375.00. Following the completion of the sale, the executive vice president now directly owns 29,186 shares in the company, valued at approximately $4,210,080.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Rick E. Winningham sold 1,241 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $138.16, for a total transaction of $171,456.56. Following the completion of the transaction, the director now directly owns 10,444 shares in the company, valued at $1,442,943.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $144.25, for a total value of $216,375.00. Following the transaction, the executive vice president now owns 29,186 shares of the company’s stock, valued at $4,210,080.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,791 shares of company stock worth $534,726. 4.40% of the stock is currently owned by insiders.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
See Also
- Five stocks we like better than Jazz Pharmaceuticals
- Large Cap Stock Definition and How to Invest
- Warren Buffett Stocks: What’s in Warren Buffett’s Portfolio?
- How to Invest in Mining Stocks
- Snack Maker Mondelez Int’l Is Down but Not Out
- The Significance of Brokerage Rankings in Stock Selection
- Costco, Dollar General, Target Up As Market Turns Defensive
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
